nach oben

Erschienen in:

27.03.2019 | Topic Review

Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis

verfasst von: Victor M. Lu, Panogiotis Kerezoudis, Desmond A. Brown, Terry C. Burns, Alfredo Quinones-Hinojosa, Kaisorn L. Chaichana

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

There is no clear consensus regarding the optimal treatment for glioblastoma (GBM) in the elderly. Hypofractionated radiation therapy (hRT) has emerged as a viable and comparable radiation regime compared to standard radiation therapy (sRT), however the survival effect of temozolomide (TMZ) with hRT is uncertain. The aim of this meta-analysis was to evaluate survival outcomes of hRT + TMZ vs sRT + TMZ in this specific demographic.

Methods

Searches of 7 electronic databases from inception to January 2019 were conducted following the appropriate guidelines. Articles were screened against pre-specified criteria. The progression free survival (PFS) and overall survival (OS) metrics were then extracted and pooled by meta-analysis evaluating mean difference (MD).

Results

A total of 7 individual comparative studies describing hRT + TMZ vs sRT + TMZ (n = 917) respectively satisfied inclusion criteria. Meta-analysis by random-effects modelling indicated that compared to sRT + TMZ, hRT + TMZ resulted in comparable PFS (MD 0.3 months; 95% CI − 2.4 to 2.9; I² = 91.7%; P-effect = 0.85) and significantly shorter OS (MD − 3.5 months; 95% CI − 6.3 to − 0.6; I² = 98.9%; P-effect = 0.02). Subgroup analysis between age definitions of elderly of > 65 vs > 70 years old both demonstrated the same significant trend with no statistical difference between the groups.

Conclusion

The combination of hRT + TMZ is feasible in well-selected elderly GBM cases, and appears to confer a statistically comparable PFS compared to sRT + TMZ. However, expectations that the OS with hRT + TMZ is comparable to that of sRT + TMZ in all elderly GBM presentations should be tempered. It is likely a specific subgroup of elderly GBM patients will benefit greatly from the addition of TMZ to hRT, and greater investigation is needed to identify their characteristics.

Nur mit Berechtigung zugänglich

Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. https://doi.org/10.1016/s1470-2045(09)70025-7 CrossRefPubMed

Palmer JD, Bhamidipati D, Mehta M, Williams NL, Dicker AP, Werner-Wasik M, Shi W (2018) Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. J Neuro-Oncol 140(2):421–426. https://doi.org/10.1007/s11060-018-2969-3 CrossRef

Braun K, Ahluwalia MS (2017) Treatment of glioblastoma in older adults. Curr Oncol Rep. https://doi.org/10.1007/s11912-017-0644-z CrossRefPubMed

Sijben AE, McIntyre JB, Roldan GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG (2008) Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neuro-Oncol 89(1):97–103. https://doi.org/10.1007/s11060-008-9593-6 CrossRef

Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. https://doi.org/10.1016/s1470-2045(12)70265-6 CrossRefPubMed

Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22(9):1583–1588. https://doi.org/10.1200/jco.2004.06.082 CrossRefPubMed

Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Wick W, van den Bent MJ (2013) Optimal management of elderly patients with glioblastoma. Cancer Treat Rev 39(4):350–357. https://doi.org/10.1016/j.ctrv.2012.05.008 CrossRefPubMed

Uto M, Mizowaki T, Ogura K, Arakawa Y, Mineharu Y, Miyamoto S, Hiraoka M (2016) Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma. Int J Clin Oncol 21(6):1023–1029. https://doi.org/10.1007/s10147-016-1014-9 CrossRefPubMed

10.

Minniti G, Scaringi C, Baldoni A, Lanzetta G, De Sanctis V, Esposito V, Enrici RM (2013) Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys 86(2):285–291. https://doi.org/10.1016/j.ijrobp.2013.02.013 CrossRefPubMed

11.

Burton E, Ugiliweneza B, Woo S, Skirboll S, Boaky M (2015) A Surveillance, Epidemiology and End Results-Medicare data analysis of elderly patients with glioblastoma multiforme: treatment patterns, outcomes and cost. Mol Clin Oncol 3(5):971–978. https://doi.org/10.3892/mco.2015.590 CrossRefPubMedPubMedCentral

12.

Glaser SM, Dohopolski MJ, Balasubramani GK, Flickinger JC, Beriwal S (2017) Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival. J Neuro-Oncol 134(1):107–118. https://doi.org/10.1007/s11060-017-2493-x CrossRef

13.

Haque W, Verma V, Butler EB, Teh BS (2018) Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival. J Neuro-Oncol 136(2):307–315. https://doi.org/10.1007/s11060-017-2654-y CrossRef

14.

Moher D, Liberati A, Tetzlaff J, Althman D (2009) Preferred Reporting Items For Systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097/ CrossRefPubMedPubMedCentral

15.

Zarnett OJ, Sahgal A, Gosio J, Perry J, Berger MS, Chang S, Das S (2015) Treatment of elderly patients with glioblastoma a systematic evidence-based analysis. JAMA Neurol 72(5):589–596. https://doi.org/10.1001/jamaneurol.2014.3739 CrossRefPubMed

16.

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327(7414):557–560CrossRef

17.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

18.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 315(7109):629–634CrossRef

19.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed

20.

Wells G, Shea B (2009) O’connell D, Peterson J, Welch V, Losos M, Tugwell P (2016) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute, Ottawa

21.

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S (2004) Grading quality of evidence and strength of recommendations. BMJ (Clin Res Ed) 328(7454):1490. https://doi.org/10.1136/bmj.328.7454.1490 CrossRef

22.

Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM (2015) Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 92(2):384–389. https://doi.org/10.1016/j.ijrobp.2015.01.017 CrossRefPubMed

23.

Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Muller-Barthelemy M, Dalloz P, Khalil T, Dillies AF, Durando X, Godfraind C, Verrelle P (2017) Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report. Radiat Oncol 12(1):197. https://doi.org/10.1186/s13014-017-0929-2 CrossRefPubMedPubMedCentral

24.

Chang-Halpenny CN, Yeh J, Lien WW (2015) Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy. Perm J 19(1):15–20. https://doi.org/10.7812/TPP/14-083 CrossRefPubMedPubMedCentral

25.

Lombardi G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E, Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P, Gurrieri L, Dall’Agata M, Eoli M, Della Puppa A, Pambuku A, D’Avella D, Berti F, Ruda R, Zagonel V (2015) Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). J Neuro-Oncol 125(2):359–367. https://doi.org/10.1007/s11060-015-1923-x CrossRef

26.

Minniti G, Scaringi C, Lanzetta G, Terrenato I, Esposito V, Arcella A, Pace A, Giangaspero F, Bozzao A, Enrici RM (2015) Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys 91(1):109–115. https://doi.org/10.1016/j.ijrobp.2014.09.013 CrossRefPubMed

27.

Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM II (2016) Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. Pract Radiat Oncol 6(5):306–314. https://doi.org/10.1016/j.prro.2015.12.001 CrossRefPubMed

28.

Lapointe S, Florescu M, Simonyan D, Michaud K (2017) Impact of standard care on elderly glioblastoma patients. Neuro-Oncol Pract 4(1):4–14. https://doi.org/10.1093/nop/npw011 CrossRef

29.

Gkogkou P, Hamm S, Geropantas K, Ajithkumar T, Jefferies S (2017) Hypofractionated versus standard radiotherapy with or without temozolomide for elderly patients with glioblastoma. In: Neuro-Oncology conference: 5th quadrennial meeting of the world federation of neuro-oncology societies, WFNOS, Switzerland, vol 19(Supplement 3), p iii71

30.

Yusuf M, Ugiliweneza B, Amsbaugh M, Boakye M, Williams B, Nelson M, Hattab EM, Woo S, Burton E (2018) Interim results of a phase II study of hypofractionated radiotherapy with concurrent temozolomide followed by adjuvant temozolomide in patients over 70 years old with newly diagnosed glioblastoma. Oncology (Switzerland) 95(1):39–42. https://doi.org/10.1159/000488395 CrossRef

31.

Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM (2012) Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83(1):93–99. https://doi.org/10.1016/j.ijrobp.2011.06.1992 CrossRefPubMed

32.

Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376(11):1027–1037. https://doi.org/10.1056/NEJMoa1611977 CrossRefPubMed

33.

Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR (2012) Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. J Neuro-Oncol 107(2):395–405. https://doi.org/10.1007/s11060-011-0766-3 CrossRef

34.

Laigle-Donadey F, Figarella-Branger D, Chinot O, Taillandier L, Cartalat-Carel S, Honnorat J, Kaloshi G, Delattre JY, Sanson M (2010) Up-front temozolomide in elderly patients with glioblastoma. J Neuro-Oncol 99(1):89–94. https://doi.org/10.1007/s11060-009-0110-3 CrossRef

35.

Gzell C, Wheeler H, Guo L, Kastelan M, Back M (2014) Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide. J Neuro-Oncol 119(1):187–196. https://doi.org/10.1007/s11060-014-1472-8 CrossRef

36.

Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6(12):937–944. https://doi.org/10.1016/s1470-2045(05)70432-0 CrossRefPubMed

37.

Ironside S, Das S, Sahgal A, Moroney C, Mainprize T, Perry JR (2017) Optimal therapies for newly diagnosed elderly patients with glioblastoma. Curr Treat Options Oncol 100:100. https://doi.org/10.1007/s11864-017-0508-7 CrossRef

38.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A (2017) Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG oncology RTOG 0525. JAMA Oncol 3(6):784–792. https://doi.org/10.1001/jamaoncol.2016.6020 CrossRefPubMedPubMedCentral

Titel: Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis
verfasst von: Victor M. Lu
Panogiotis Kerezoudis
Desmond A. Brown
Terry C. Burns
Alfredo Quinones-Hinojosa
Kaisorn L. Chaichana
Publikationsdatum: 27.03.2019
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03155-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis

Abstract

Background

Methods

Results

Conclusion

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Correlation of the invasive potential of glioblastoma and expression of caveola-forming proteins caveolin-1 and CAVIN1

Identification of PEPT2 as an important candidate molecule in 5-ALA-mediated fluorescence-guided surgery in WHO grade II/III gliomas

Canadian patterns of practice for intracranial germ cell tumors in adolescents and young adults

Clinical diagnosis of attention-deficit/hyperactivity disorder in survivors of pediatric brain tumors

Gamma knife radiosurgery for the treatment of cavernous sinus meningiomas: post-treatment long-term clinical outcomes, complications, and volume changes

Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie